Sirtuin 3 deficiency does not alter host defenses against bacterial and fungal infections.

Détails

Ressource 1Télécharger: s41598-017-04263-x.pdf (1823.35 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_CE9836DB152C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Sirtuin 3 deficiency does not alter host defenses against bacterial and fungal infections.
Périodique
Scientific reports
Auteur(s)
Ciarlo E., Heinonen T., Lugrin J., Acha-Orbea H., Le Roy D., Auwerx J., Roger T.
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Statut éditorial
Publié
Date de publication
20/06/2017
Peer-reviewed
Oui
Volume
7
Numéro
1
Pages
3853
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
Sirtuin 3 (SIRT3) is the main mitochondrial deacetylase. SIRT3 regulates cell metabolism and redox homeostasis, and protects from aging and age-associated pathologies. SIRT3 may drive both oncogenic and tumor-suppressive effects. SIRT3 deficiency has been reported to promote chronic inflammation-related disorders, but whether SIRT3 impacts on innate immune responses and host defenses against infections remains essentially unknown. This aspect is of primary importance considering the great interest in developing SIRT3-targeted therapies. Using SIRT3 knockout mice, we show that SIRT3 deficiency does not affect immune cell development and microbial ligand-induced proliferation and cytokine production by splenocytes, macrophages and dendritic cells. Going well along with these observations, SIRT3 deficiency has no major impact on cytokine production, bacterial burden and survival of mice subjected to endotoxemia, Escherichia coli peritonitis, Klebsiella pneumoniae pneumonia, listeriosis and candidiasis of diverse severity. These data suggest that SIRT3 is not critical to fight infections and support the safety of SIRT3-directed therapies based on SIRT3 activators or inhibitors for treating metabolic, oncologic and neurodegenerative diseases without putting patients at risk of infection.
Mots-clé
Animals, Bacterial Infections/genetics, Biomarkers, Dendritic Cells/immunology, Dendritic Cells/metabolism, Disease Resistance/genetics, Host-Pathogen Interactions/genetics, Humans, Immunophenotyping, Macrophages/immunology, Macrophages/metabolism, Mice, Mice, Knockout, Mycoses/genetics, Sirtuin 3/deficiency, Thymocytes/immunology, Thymocytes/metabolism
Pubmed
Web of science
Open Access
Oui
Création de la notice
26/06/2017 8:38
Dernière modification de la notice
20/08/2019 16:49
Données d'usage